The Clinical Eye Research Unit (CERU) at the University of Wisconsin–Madison Department of Ophthalmology and Visual Sciences has been instrumental in the approval of a new treatment option for patients with exudative age-related macular degeneration (wet AMD).
CERU
SANDCAT
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Uveitic Macular Edema (Sandcat)
CapriCORN
Comprehensive Analysis of Pathogens, Resistomes, and Inflammatory-markers in the Cornea
RECORDATI MT8
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops (MT8) for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
IMVT TED
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
Clinical Trial Offers Hope to Patients with Dry Age-Related Macular Degeneration
A current clinical trial could lead to approval of a first-ever treatment option for patients with geographic atrophy (GA) secondary to age-related macular degeneration, a progressive, irreversible, and devastating eye disease.
Funds Distribution Committee Supports New Projects
The Funds Distribution Committee has announced a new round of projects selected to receive funding: Clinical Eye Research Unit’s purchase of an Optos Widefield Camera, $50,000 Ismail Zaitoun, PhD, and Nader Sheibani, PhD, for their …